4.6.2 Migraine and Headache
NHS Kent & Medway guidance on the use of Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults. Please Click Here
Migraines and Headaches - Management of Adults with Headaches and Migraines in Primary Care Guidance and Migraine referral Form Click Here
  Erenumab (Aimovig®) |
This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA682 |
| For more information and NICE Guidance Click Here | Erenumab for preventing migraine NICE Guidance TA682 ICB commissioned - approval via Blueteq |
|
|
This High-Cost Drug has been approved for the following indications: - for for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA871 |
| For more information and NICE Guidance Click Here | Eptinezumab for preventing migraine NICE Guidance TA871 ICB commissioned - approval via Blueteq |
Fremanezumab (Ajovy®) |
This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA764 |
| For more information and NICE Guidance Click Here | Fremanezumab for preventing migraine NICE Guidance TA764 ICB commissioned - approval via Blueteq |
|
|
This High-Cost Drug has been approved for the following indications: - for for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA659 |
| For more information and NICE Guidance Click Here | Galcanezumab for preventing migraine NICE Guidance TA659 ICB commissioned - approval via Blueteq |
|
|
This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA906 -Acute treatment of migraine with or without aura in adults as per NICE TA919 |
| For more information and NICE Guidance Click Here |
Rimegepant for preventing migraine NICE Guidance TA906 ICB commissioned - approval via Blueteq |
|
Rimegepant for Acute treatment of migraine with or without aura in adults NICE Guidance TA919 |
| Pack |
|---|
| 12 tablet |
| 2 tablet |
| 4 tablet |
| 6 tablet |
| Pack |
|---|
| 12 tablet |
| 2 tablet |
| 4 tablet |
| 6 tablet |
| Pack |
|---|
| 2 unit dose |
| Pack |
|---|
| 2 unit dose |
| 6 unit dose |
| Pack |
|---|
| 2 pre-filled disposable injection |
| Pack |
|---|
| 28 tablet |
| 60 tablet |
| 84 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 3 tablet |
| 6 tablet |
| Pack |
|---|
| 12 tablet |
| 2 tablet |
| 3 tablet |
| 6 tablet |
| Pack |
|---|
| 3 tablet |
| 6 tablet |
| Pack |
|---|
| 3 tablet |
| 6 tablet |
| Pack |
|---|
| 6 unit dose |
| Pack |
|---|
| 6 tablet |
| Pack |
|---|
| 12 tablet |
| 6 tablet |
| Pack |
|---|
| 6 tablet |
| Pack |
|---|
| 12 tablet |
| 6 tablet |
NHS Kent & Medway guidance on the use of Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults. Please Click Here
| Pack |
|---|
| 1 vial |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only